Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.25 ▼ -0.05
(-3.85%)
MKT CAP: $431.9M • VOL: 7.71M
52W L $1 52W H $4
ROARABLE / RQD
D- • 38/100
PIOTROSKI
3 / 9
ALLO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $22.0K | $95.0K |
| YoY Revenue Growth % | — | -76.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$209.3M | -$273.2M | -$327.7M |
| Operating Margin % | — | -80.0% | -80.0% |
| Net Income (GAAP) | -$190.9M | -$257.6M | -$327.3M |
| EBITDA (Normalized) | -$209.0M | -$272.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$149.2M | -$200.3M | -$237.7M |
| Capital Expenditures (CapEx) | $386.0K | $694.0K | — |
| Free Cash Flow (FCF) | -$149.6M | -$201.0M | -$237.7M |
| FCF Margin % | — | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $51.7M | $75.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $292.5M | $422.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ALLO.